



2022 Ryan White HIV/AIDS Program CLINICAL CONFERENCE

San Diego, California | October 16-18, 2022



30
YEARS
OF
RESEARCH
AND
CARE

 IAS-USA
International Antiviral Society-USA

CONTENTS

CONTENTS	1
GENERAL INFORMATION.....	3
WELCOME AND GOALS	3
OVERVIEW	3
CONFERENCE FUNDING.....	3
MEALS AND INCIDENTALS	3
WEBSITE	3
WEBCASTS AND PODCASTS.....	3
POST-CONFERENCE MATERIALS AND RESOURCES.....	3
DRUG AND PRODUCT DISCLAIMER	4
WI-FI ACCESS AT THE CONFERENCE	4
REGISTRATION AND INFORMATION DESK HOURS	4
BADGES.....	4
CONFERENCE ETIQUETTE	4
CLIMATE AND CLOTHING	4
CHILD CARE AND NEW MOTHERS	4
NETWORKING RECEPTION AND ROOMS.....	4
THE HIV/AIDS BUREAU OF THE HEALTH RESOURCES AND SERVICES ADMINISTRATION.....	5
INTERNATIONAL ANTIVIRAL SOCIETY–USA	6
MISSION	6
SCIENTIFIC LEADERSHIP BOARD	6
IAS–USA GOVERNANCE.....	6
IMPROVING THE MANAGEMENT OF HIV DISEASE®: ADVANCED CME COURSES IN HIV PATHOGENESIS, ANTIRETROVIRALS, AND OTHER SELECTED ISSUES IN HIV DISEASE MANAGEMENT.....	6
WEBINARS	6
CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS	6
<i>TOPICS IN ANTIVIRAL MEDICINE™</i>	6
TREATMENT AND TESTING GUIDELINES.....	6
DRUG RESISTANCE MUTATIONS PROJECT	7
COVID-19: WHAT WE KNOW TODAY. A DIALOGUE ABOUT THE PUBLIC HEALTH, SCIENTIFIC, AND CLINICAL ASPECTS OF THE PANDEMIC.....	7
PODCASTS.....	7
PRACTICE QUESTION OF THE WEEK.....	7
PRESENTATION SLIDES	7
AIDS EDUCATION AND TRAINING CENTER NATIONAL COORDINATING RESOURCE CENTER....	8
CONFERENCE CO-CHAIRS AND FACULTY.....	9
CONFERENCE FACULTY AND ORGANIZER’S FINANCIAL RELATIONSHIPS WITH INELIGIBLE COMPANIES (FORMERLY DESCRIBED AS COMMERCIAL INTERESTS BY THE ACCME).....	11
FACULTY FINANCIAL DISCLOSURE	11
CONFERENCE CO-CHAIRS.....	12
SPEAKERS AND BREAKOUT SESSION LEADERS	12
CONTINUING EDUCATION CREDITS.....	13
ACCREDITATION STATEMENT AND CME CREDITS.....	13
ABIM MOC POINTS FOR INTERNAL MEDICINE SPECIALISTS AND SUBSPECIALISTS	13

NURSING CONTINUING EDUCATION CONTACT HOURS	13
PHARCY CONTINUING EDUCATION CONTACT HOURS.....	13
AMERICAN ACADEMY OF FAMILY PHYSICIANS (AAFP) CREDITS.....	13

GENERAL INFORMATION

WELCOME AND GOALS

Welcome to the **2022 Ryan White HIV/AIDS Program (RWHAP) CLINICAL CONFERENCE**. The goals of the **2022 CLINICAL CONFERENCE** are to:

- Provide key updates in HIV medicine for practitioners in RWHAP-funded clinics and programs
- Facilitate networking and collaborations among attendees
- Equip attendees with information and tools for sharing this key information with clinic staff and colleagues

OVERVIEW

The **2022 RWHAP CLINICAL CONFERENCE** will provide state-of-the-art updates on research, care, and treatment issues in the medical management of HIV infection for experienced HIV clinical decision makers.

The **2022 RWHAP CLINICAL CONFERENCE** is planned with and supported by the HIV/AIDS Bureau, Health Resources and Services Administration of the US Department of Health and Human Services (HRSA) and is sponsored and organized by the International Antiviral Society-USA (IAS-USA). This conference is coordinated through the AIDS Education and Training Centers (AETC) clinician training network. A mix of lectures, case-based interactive presentations, and small-group breakout sessions will be held during the 3 days of the **2022 RWHAP CLINICAL CONFERENCE**.

CONFERENCE FUNDING

This conference is funded by the Health Resources and Services Administration (HRSA) of the US Department of Health and Human Services (HHS) under grant number U1OHA28686.

The networking reception is supported in-kind by the IAS-USA.

Daily coffee is provided in-kind by the Wyndham San Diego Bayside.

MEALS AND INCIDENTALS

Attendees are responsible for their transportation expenses to and from the conference, hotel stay costs, meals, and all other expenses. Meals will NOT be provided, but complimentary coffee will be provided by the hotel each morning. Please check with your project officer about expenses that are covered by your RWHAP award. Per diem meal options will be available onsite.

WEBSITE

For additional information about the **2022 CLINICAL CONFERENCE** please visit the website at <https://www.iasusa.org/events/rwhap2022/>



WEBCASTS AND PODCASTS

Webcasts and podcasts of the plenary lectures will be available within 10 business days following the conclusion of the conference. Please note: meet-the-expert breakout sessions are not recorded.

POST-CONFERENCE MATERIALS AND RESOURCES

As you know, an important goal of the **2022 RWHAP CLINICAL CONFERENCE** is to provide attendees with the resources to update their clinical colleagues who were not able to attend the conference. To that end, a Slide Training Guide with PowerPoint slides and webcasts of each plenary lecture are available after the **2022 RWHAP CLINICAL CONFERENCE** concludes. About 2 months after the conference, you will be asked to summarize the postconference updates and trainings that you have conducted for you clinic staff and colleagues.

GENERAL INFORMATION (CONTINUED)

DRUG AND PRODUCT DISCLAIMER

This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.

The views and opinions expressed are those of the faculty and do not necessarily represent the opinions or recommendations of the IAS–USA.

WI-FI ACCESS AT THE CONFERENCE

Complimentary Wi-Fi access is provided at the Wyndham San Diego Bayside. Network information is as follows:

1. Your Internet Network ID is: **RyanWhite2022**
2. Your password is: **iasusa2022**
(case sensitive)

REGISTRATION AND INFORMATION DESK HOURS

The hours of the **2022 RWHAP CLINICAL CONFERENCE** registration and information desk, located on the outside the conference area are as follows:

Saturday, October 15:	3:00 PM – 6:00 PM
Sunday, October 16:	10:00 AM – 5:00 PM
Monday, October 17:	8:00 AM – 5:30 PM
Tuesday, October 18:	8:00 AM – 5:00 PM

BADGES

When you arrive at the **2022 RWHAP CLINICAL CONFERENCE**, please check in at the registration desk to sign in and to pick up your name badge. You must have your name badge in order to access the conference, breakout session, and reception rooms.

CONFERENCE ETIQUETTE

Please ensure all cell phones and pagers are off or are placed in SILENT mode in the meeting rooms. No flash photography is permitted in meeting rooms.

CLIMATE AND CLOTHING

Please check area forecasts before departing for the conference. Attire for the conference is business casual. Meeting rooms have the tendency to be quite cool; we advise you to dress accordingly.

CHILD CARE AND NEW MOTHERS

Children are not permitted in the meeting rooms, and child care will not be provided by the conference. If you are travelling with young children, please make arrangements in advance for child care during the conference sessions. There are nanny services available in San Diego area.

Private and semi-private areas are available for nursing mothers. Please go to the IAS–USA Office in the East Coast room and speak with a staff member about the options.

NETWORKING RECEPTION AND ROOMS

The IAS–USA-hosted networking reception will be on Monday, October 17, from 5:30 PM to 7:00 PM on the terrace.

Networking space is located on the first floor in the Embarcadero room and the Bayside room. Tables are on a first-come, first-serve basis. The space cannot be reserved.

THE HIV/AIDS BUREAU OF THE HEALTH RESOURCES AND SERVICES ADMINISTRATION

The Health Resources and Services Administration (HRSA), an agency of the U.S. Department of Health and Human Services, is the primary federal agency for improving health care for people who are geographically isolated, or economically or medically vulnerable. Tens of millions of Americans receive quality, affordable health care and other services through HRSA's 90-plus programs and more than 3,000 grantees.

The HRSA HIV/AIDS Bureau Ryan White HIV/AIDS Program (RWHAP) provides a comprehensive system of HIV primary medical care, essential support services, and medications for low-income people with HIV who are uninsured and underserved. The Program funds grants to states, cities/counties, and local community-based organizations to provide care and treatment services to people with HIV to improve health outcomes and reduce HIV transmission.

More than half of people with diagnosed HIV in the U.S. receive services through the RWHAP each year. That means more than half a million people received services through the Program.

Over the last 32 years, HRSA's RWHAP has played a critical role in the U.S. public health response to HIV. The Program serves as an important source of ongoing access to HIV medication that can enable people with HIV to live close to normal lifespans. In 2020, 89.4% of RWHAP clients were virally suppressed, which exceeds the national average of 65.5%.

Funded through a cooperative agreement with HRSA, the RWHAP Clinical Conference further supports the principles of the HIV/AIDS Bureau and HRSA.

INTERNATIONAL ANTIVIRAL SOCIETY–USA

MISSION

The mission of the International Antiviral Society–USA (IAS–USA) is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV or other viral infections and their associated health conditions through high-quality, relevant, balanced, and needs-oriented education and information for practitioners and scientists who are actively involved in medical care and research.

SCIENTIFIC LEADERSHIP BOARD

The Scientific Leadership Board of volunteers guides the needs assessment, design, development, and evaluation of the educational and scientific programming of the in-person and virtual courses, webinars and *Topics in Antiviral Medicine*[™]. Visit <https://www.iasusa.org/about/ias-usa-scientific-leadership-board/> for a list of Scientific Leadership Board members.

IAS–USA GOVERNANCE

The IAS–USA Governance members provide administrative oversight for the operations and mission of the IAS–USA. Non-Staff Members serve in a volunteer capacity and are not compensated for their roles in oversight and governance of the organization. Visit <https://www.iasusa.org/about/ias-usa-governance/> for a list of IAS–USA Governance members.

IMPROVING THE MANAGEMENT OF HIV DISEASE®: ADVANCED CME COURSES IN HIV PATHOGENESIS, ANTIRETROVIRALS, AND OTHER SELECTED ISSUES IN HIV DISEASE MANAGEMENT

These one-day courses are designed for HIV specialists who are actively involved in HIV disease management or research. The virtual courses are half-day updates that focus on the key issues clinicians are likely facing. Nationally and internationally recognized faculty provide advanced-level presentations with balanced, timely, scientifically rigorous, and clinically relevant information about HIV disease management. Visit www.iasusa.org/activities/live-courses/hiv-courses/ for more information on upcoming and on-demand CME courses.

WEBINARS

The IAS–USA offers state-of-the-art webinars on the evolving challenges of managing HIV disease as part of a nationwide continuing medical education (CME) effort for physicians. They are led by nationally and internationally recognized faculty. Each webinar lasts 75 to 90 minutes and provides continuing education credits. Visit www.iasusa.org/activities/webinars/upcoming-webinars/ for upcoming webinars. On-demand webinars offer CME credit for a year at www.iasusa.org/activities/webinars/on-demand-webinars/.

Webinar topics and presenters are identified by the *Cases on the Web Board (COW)* Board, a select group of experts in the management of HIV and other viral infections. Visit www.iasusa.org/activities/cases-on-the-web/about-cows/cow-webinars-editorial-board/ for a list of COW Board members.

CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS

The IAS–USA partners with the Conference on Retroviruses and Opportunistic Infections (CROI) Foundation to sponsor CROI, the most important HIV research conference worldwide. Webcasts, electronic posters, and abstracts from CROI 2014 to 2022 are available at www.CROIconference.org.

CROI 2023 will be held in Seattle, Washington, from February 19 to 22, 2022.

TOPICS IN ANTIVIRAL MEDICINE[™]

The IAS–USA publishes the peer-reviewed journal *Topics in Antiviral Medicine*[™] 4 to 6 times a year as a resource for physicians and other health care practitioners who are actively involved in the care of people with HIV or other viral infections. The journal offers CME credit and is indexed on Index Medicus/MEDLINE. Visit <https://www.iasusa.org/activities/topics-in-antiviral-medicine/current-issues/> to view the journal.

TREATMENT AND TESTING GUIDELINES

The IAS–USA sponsors the development of clinical practice guidelines. The guidelines are written by independent volunteer panels of researchers and clinicians from around the world and focus on management issues for which definitive evidence is lacking. Guidelines for viral load testing, antiretroviral therapy, behavioral and biomedical HIV prevention, HIV drug resistance testing,

cytomegalovirus infection, and metabolic complications have been published.

Recommendations on the use of antiretroviral drugs for treatment and prevention of HIV infection in adults, by the IAS–USA volunteer Antiretroviral Guidelines Panel, were last published in the *Journal of the American Medical Association* on October 14, 2020 (Saag MS, Gandhi RT, Hoy JF et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society–USA panel. *JAMA*. 2020:E1-19). *JAMA* offers free access to the paper at

www.jamanetwork.com/journals/jama/fullarticle/2771873.

The paper includes updated recommendations for the use of antiretroviral therapy in adults with established HIV infection, including new recommendations on what regimens to start, updated approaches to prescribing preexposure prophylaxis (PrEP), new recommendations on management of aging among people with HIV, and overview of the then understanding of the intersection of COVID-19 disease and HIV.

DRUG RESISTANCE MUTATIONS PROJECT

Through the HIV Drug Resistance Mutations Panel, the IAS–USA provides regular updates on the mutations associated with resistance to antiretroviral drugs. A volunteer panel of acknowledged leaders in the field collect and review the information on relevant mutations. This information, last updated in October 2022, is available on the IAS–USA website at www.iasusa.org/resources/hiv-drug-resistance-mutations/.

COVID-19: WHAT WE KNOW TODAY. A DIALOGUE ABOUT THE PUBLIC HEALTH, SCIENTIFIC, AND CLINICAL ASPECTS OF THE PANDEMIC

The COVID-19 pandemic has created an urgent need for reliable scientific information. The IAS–USA COVID-19 Dialogues bring together 2 or more leading experts to discuss the latest science regarding COVID-19 and what the data and research are telling us about the basic science, public health, and clinical aspects of the disease, and the consequences of the pandemic.

Visit <https://www.iasusa.org/activities/covid-19-dialogue-series/> for upcoming live Dialogues. The conversations are available on-demand as webcasts and podcasts after they are broadcast at www.iasusa.org/activities/covid-19-dialogue-series/on-demand/.

PODCASTS

Many past IAS–USA activities are available as podcasts and may be downloaded from the IAS–USA website. Visit www.iasusa.org/resources/podcasts for details and a list of available presentations.

PRACTICE QUESTION OF THE WEEK

This initiative started in 2021 and highlights updates to relevant practice guidelines or identified practice gaps. Each question is programmed as a pop-up and on the [resources page](#) on the IAS–USA website. Participants receive immediate feedback with the correct answer, explanation, and links to more resources. Visit <https://www.iasusa.org/practice-question-of-the-week/> to view the most recent question and to see past questions.

PRESENTATION SLIDES

The IAS–USA offers a collection of downloadable slides from presentations at conferences or past IAS–USA live courses. Presenters have selected the slides they consider the most informative and relevant. Slides may be downloaded as PowerPoint files from the IAS–USA website at www.iasusa.org/resources/key-slides/.



For information about any of these programs, please visit www.IAS-USA.org.

Email: info@iasusa.org • Phone: (415) 544-9400

AIDS EDUCATION AND TRAINING CENTER NATIONAL COORDINATING RESOURCE CENTER

The AIDS Education and Training Center National Coordinating Resource Center (AETC NCRC) provides education, capacity building, and other training resources for regional AETCs along with the coordination and organization of AETC network communities of practice to support the mission to offer timely, high-quality, state-of-the-science information to health care professionals working with existing and emerging populations affected by HIV. The AETC Program is a Ryan White HIV/AIDS


program consisting of a network of AETC programs: 8 regional AETCs, 3 national AETCs, and 5 health profession training programs. This project is supported by the Health Resources and Services Administration (HRSA) of the US Department of Health and Human Services (HHS) under grant number U1OHA28686 awarded to the François-Xavier Bagnoud Center from the Rutgers University School of Nursing.

CONFERENCE CO-CHAIRS AND FACULTY

CO-CHAIRS



Laura W. Cheever, MD, ScM
Associate Administrator
Chief Medical Officer
HIV/AIDS Bureau
Health Resources and Services Administration
Rockville, Maryland



Michael S. Saag, MD
Professor of Medicine
Associate Dean for Global Health
University of Alabama at Birmingham
Birmingham, Alabama




Roger J. Bedimo, MD, MS
Chief, Infectious Diseases Section
VA North Texas Health Care System
Professor of Medicine
UT Southwestern Medical Center
Dallas, Texas

SPEAKERS, PANELISTS, AND BREAKOUT SESSION LEADERS



Laura Bachmann, MD, MPH
Chief Medical Officer, Division of STD Prevention
Centers for Disease Control and Prevention
Atlanta, Georgia



Jason Farley, PhD, MPH, ANP-BC
Endowed Professor of Nursing Innovation and
Leadership
Johns Hopkins University School of Nursing
Baltimore, Maryland



Constance A. Benson, MD
Professor of Medicine and Global Public Health
University of California San Diego
San Diego, California



Rajesh T. Gandhi, MD
Professor of Medicine
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts




Jill Blumenthal, MD, MAS
Associate Professor of Medicine
University of California San Diego
San Diego, California



Steven C. Johnson, MD
Professor of Medicine
University of Colorado
Aurora, Colorado




Philip J. Bolduc, MD
HIV Program Director
Family Health Center of Worcester
Worcester, Massachusetts




Nadine J. Kaslow, PhD
Professor of Psychiatry and Behavioral Sciences
Emory University
Atlanta, Georgia



John T. Brooks, MD
Chief Medical Officer, Division of HIV/AIDS
Prevention
Centers for Disease Control and Prevention
Atlanta, Georgia



H. Nina Kim, MD, MS
Adjunct Professor, Global Health
Professor of Medicine, Allergy, and Infectious
Diseases
University of Washington
Seattle, Washington



R. Douglas Bruce, MD, MA, MS
Associate Professor of Medicine
Boston University
Boston, Massachusetts



Richard Koup, MD
Chief of Immunology Laboratory
Vaccine Research Center, National Institute of
Allergy and Infectious Diseases, National
Institutes of Health
Bethesda, Maryland



Edward R. Cachay, MD
Professor of Medicine
University of California San Diego
San Diego, California



Judy Levison, MD, MPH
Professor of Obstetrics and Gynecology
Baylor College of Medicine
Houston, Texas



Henry Masur, MD
Clinical Professor of Medicine
The George Washington University
Washington, DC



Aadia I. Rana, MD
Associate Professor of Medicine
University of Alabama at Birmingham
Birmingham, Alabama



William Christopher Mathews, MD
Professor of Medicine
University of California San Diego
San Diego, California



David H. Spach, MD
Principal Investigator
Mountain West AIDS Education and Training Center
Professor of Medicine
University of Washington School of Medicine
Seattle, Washington



Lisa C. Navracruz, MD
Family Physician
Neighborhood Family Practice
Cleveland, Ohio



Timothy J. Wilkin, MD, MPH
Professor of Medicine
Weill Cornell Medicine
New York, New York

CONFERENCE FACULTY AND ORGANIZER'S FINANCIAL RELATIONSHIPS WITH INELIGIBLE COMPANIES (FORMERLY DESCRIBED AS COMMERCIAL INTERESTS BY THE ACCME)

FACULTY FINANCIAL DISCLOSURE

It is the policy of IAS–USA to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All parties with control over the content of IAS–USA activities (eg, conference co-chairs, faculty, and IAS–USA staff) are required to disclose to the organization and activity audience any financial relationships with ineligible companies (formerly described as commercial interests by the ACCME) within the previous 24 months.

The **ACCME defines ineligible companies** as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”

It is IAS–USA policy to separate ineligible company promotion from its core educational and informational activities. Individuals who conduct marketing or promotional activities for ineligible companies may not contribute to IAS–USA programs. A marketing or promotional activity includes any activity in which the ineligible company controls key elements, such as speaker or topic selection that could be used to serve the ineligible company's interests (eg, speakers' bureaus, lectures, and advertorials). Individuals may not

participate in most IAS–USA programs for 12 months after functioning in a promotional or marketing effort for an ineligible company.

IAS–USA policy requires that it resolve any real or apparent conflict of interest that may influence the development, content, or delivery of its educational activities prior to the activity being delivered to participants.

The IAS–USA has several mechanisms for resolving conflicts of interest in educational activities. If the conflict of interest cannot be resolved through these mechanisms, the party is recused from the activity.

It is the policy of IAS–USA to publish the financial relationships with ineligible companies of all parties in control of the content of its activities on activity materials or, in cases where space is limited (eg, reprints of figures), on the IAS–USA website, through a web address printed on the activity material. This information will also be provided directly by the IAS–USA office upon request. Individuals who refuse to disclose financial relationships with ineligible companies will not participate in the CME activity.

CONFERENCE FACULTY AND ORGANIZER'S FINANCIAL RELATIONSHIPS WITH INELIGIBLE COMPANIES (FORMERLY DESCRIBED AS COMMERCIAL INTERESTS BY THE ACCME) (CONTINUED)

Below are the financial relationships with ineligible companies that faculty members of this conference have had within the past 24 months as of the date listed.

CONFERENCE CO-CHAIRS

Dr Bedimo has received research funding from ViiV Healthcare and Merck & Co. Inc, and serves on the Scientific Advisory Board for Merck & Co, Inc, ViiV Healthcare, Gilead Sciences, Inc, and Theratechnologies. (Updated 9/6/22)

Dr Cheever has no relevant financial relationships with ineligible companies to disclose. (Updated 09/29/22)

Dr Saag has received research grants and support awarded to his institution from Gilead Sciences, Inc and ViiV Healthcare. (Updated 07/19/22)

SPEAKERS AND BREAKOUT SESSION LEADERS

Dr Bachmann has no financial relationships with ineligible companies to disclose. (Updated 03/04/22)

Dr Johnson has served on an advisory board for and received consultation fees to his institution from ViiV Healthcare. (Updated 10/17/22)

Dr Bedimo has received research funding from ViiV Healthcare and Merck & Co. Inc, and serves on the Scientific Advisory Board for Merck & Co, Inc, ViiV Healthcare, Gilead Sciences, Inc, and Theratechnologies. (Updated 9/6/22)

Dr Kaslow has no relevant financial relationships with ineligible companies to disclose. (Updated 09/29/22)

Dr Benson has served on advisory and data safety monitoring boards for GlaxoSmithKline/ViiV Healthcare, received research grants awarded to her institution from Gilead Sciences, Inc., and serves as a consultant to NDA Partners, LLC. (Updated 09/27/22)

Dr Kim has received grants paid to her institution from Gilead Sciences, Inc. (Updated 10/01/22)

Dr Blumenthal has received research support paid to her institution from Gilead Sciences, Inc. (Updated 6/09/22)

Dr Koup has no relevant financial relationships with ineligible companies to disclose. (Updated 10/01/22)

Dr Bolduc has no relevant financial relationships with ineligible companies to disclose. (Updated 09/27/22)

Dr Landovitz has served on the scientific advisory board for Gilead Sciences, Inc. (Updated 05/05/22)

Dr. Brooks has no relevant financial relationships with ineligible companies to disclose. (Updated 10/04/22)

Dr Levison has no relevant financial relationships with ineligible companies to disclose. (Updated 09/29/22)

Dr Bruce has no relevant financial relationships with ineligible companies to disclose. (Updated 10/04/22)

Dr Masur has no relevant financial relationships with ineligible companies to disclose. (Updated 10/13/22)

Dr Cachay has served as a consultant for Theratechnologies, and has received research grants awarded to her institution from Gilead Sciences, Inc. (Updated 10/04/22)

Dr Mathews has no relevant financial relationships with ineligible companies to disclose. (Updated 10/17/22)

Dr Cheever has no relevant financial relationships with ineligible companies to disclose. (Updated 09/29/22)

Dr Rana has received grants paid to her institution from Merck & Co, Inc. (Updated 09/29/22)

Dr Farley has no relevant financial relationships with ineligible companies to disclose. (Updated 10/10/22)

Dr Saag has received research grants and support awarded to his institution from Gilead Sciences, Inc and ViiV Healthcare. (Updated 07/19/22)

Dr Gandhi has no relevant financial relationships with ineligible companies to disclose. (Updated 09/28/22)


Dr Spach has no financial relationships with ineligible companies to disclose. (Updated 10/04/22)

Dr Wilkin has served as an ad hoc consultant for Merck. Dr Wilkin receives grant support paid to his institution from Merck. (Updated 10/13/2022)

CONTINUING EDUCATION CREDITS


ACCREDITATION STATEMENT AND CME CREDITS

Physicians (MD, DO, and international equivalents) are eligible to receive CME credit for participation in the **2022 RWHAP CLINICAL CONFERENCE**.

 The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of **15.75 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC POINTS FOR INTERNAL MEDICINE SPECIALISTS AND SUBSPECIALISTS

 Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to **15.75 MOC points** in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

NURSING CONTINUING EDUCATION CONTACT HOURS


Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for **15.75** hours of continuing nursing education.

Educational Review Systems is also approved for nursing continuing education by the state of

California, the state of Florida and the District of Columbia.

This program is approved for **15.75** hours of pharmacotherapy credit.

PHARCY CONTINUING EDUCATION CONTACT HOURS

 Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for **15.75** contact hours (1.575 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event. Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time. The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.

AMERICAN ACADEMY OF FAMILY PHYSICIANS (AAFP) CREDITS

The AAFP has reviewed The 2022 Ryan White HIV/AIDS Program CLINICAL CONFERENCE and deemed it acceptable for up to **15.25** Live AAFP Prescribed credits. Term of Approval is from 10/16/2022 to 10/18/2022. Physicians should claim only the credit commensurate with the extent of their participation in the activity.